TriSalus Life Sciences, Inc. 8-K

What Happened
TriSalus Life Sciences, Inc. announced its financial results for the first quarter ended March 31, 2026 via a press release issued on May 12, 2026. The company filed a Form 8-K (Item 2.02) attaching that press release as Exhibit 99.1; the 8-K was signed by CFO David Patience on May 12, 2026.

Key Details

• Filing date: May 12, 2026.
• Reporting period: Quarter ended March 31, 2026.
• Disclosure: Press release attached as Exhibit 99.1 and an Inline XBRL cover page (Exhibit 104).
• Legal note: The press release/exhibit is furnished under Item 2.02 and explicitly will not be deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings unless specifically stated.

Why It Matters
This 8-K signals that TriSalus has published its quarterly earnings and related operating results; investors should read the attached press release for revenue, net income/loss, operating cash flow, and any commentary on business trends or guidance. Note the company’s statement that the release is furnished (not “filed”), which affects legal liability and how the information may be used in other SEC filings.